Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common herpes drug ease cancer treatment's painful mouth sores?

NCT ID NCT07363031

Symptom relief Sponsor: Instituto Oncoclinicas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the antiviral drug valacyclovir can prevent or reduce painful mouth sores (oral mucositis) in adults receiving radiotherapy for head and neck cancer. Researchers will give either valacyclovir or a placebo to 84 participants during their radiation treatment. They will monitor mouth sores, pain, and herpesvirus activity to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Valacyclovir
What this could lead to
If it works, this could point toward a simple antiviral pill to prevent severe mouth sores during head and neck cancer radiotherapy.
What could go wrong
This is a small, early-phase trial. The benefit may be small or absent, and valacyclovir can cause side effects like nausea or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of head and neck cancer. * Planned to receive curative or definitive radiotherapy to the head and neck region. * Ability to swallow oral medication. * Adequate clinical condition to participate in study procedures. * Ability to provide written informed consent. Exclusion Criteria: * Known hypersensitivity or contraindication to valacyclovir or related antiviral agents. * Current or recent use of systemic antiviral therapy. * Severe renal impairment requiring dose adjustment or contraindicating valacyclovir use. * Active oral infection requiring systemic antimicrobial treatment at baseline. * Pregnant or breastfeeding individuals. * Participation in another interventional clinical trial that may interfere with study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer (H&N) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms stomatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer (H&N) Oral mucositis Radiotherapy side effects

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto Oncoclinicas

    Rio de Janeiro, Rio de Janeiro, 22250-905, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.